PLANET-TRACKER
26.6.2024 17:01:35 CEST | Business Wire | Press release
Access to Nutrition Initiative (ATNI) and Planet Tracker, in association with The Global Alliance for Improved Nutrition, have published a seminal Materiality of Nutrition Report. The first collaboration between ATNI and Planet Tracker sets the scene for a new conversation – how can healthier foods drive healthy profits, people and planet?
The report compares the healthiness of food product portfolios from 20 of the largest global food manufacturers with their profits and market valuations. The findings reveal a link between healthier food product portfolios and higher profitability but this is obscured by poor company disclosures.
Key Findings
NB: The sample size is only 20 companies. Neither ATNI nor Planet Tracker wish to suggest this report is more than a discussion paper to stimulate further debate.
Health & Profitability: Analysis shows that companies with broader, healthier food portfolios have higher average profit margins (15.2%) compared to those with unhealthy portfolios (13.4%). However, a subset specializing in unhealthy products, like soft drinks, shows even higher margins (16.7%), highlighting the complexity of the market.
Health Star Rating (HSR) and EBIT: Understanding the relationship between HSR and EBIT is key to drive investments towards health and wealth. Our findings suggest there is not a strong negative association, in the companies assessed, between HSR and EBIT. What’s more, our results suggest there are positive associations between HSR and EBIT among smaller companies with broad portfolios.
Investment Opportunities: In addition to the obvious benefits to society, investors would benefit from a switch to healthier foods. In a scenario where companies with unhealthy portfolios switch to healthier products and achieved similar margins, profits would also rise by nearly USD 350 million and valuations by USD 60 billion.
Investment risks: Most companies fail to provide sufficient information, making it difficult for investors to assess the impact of nutrition on their valuations. This lack of transparency is a missed opportunity for companies and a risk for investors, particularly with potential regulations on the horizon.
Social & Economic Impact: Unhealthy food products reduce productivity, increase costs for employers, and impose a significant burden on society, potentially reducing GDP by 3.3% and life expectancy by three years by 2050.
Policy & Regulation: Effective policy actions in various countries signal rising pressure for broader regulation, posing risks (and opportunities) or companies relying on unhealthy products and the financial institutions that support them.
Greg S Garrett, Executive Director, Access to Nutrition Initiative,
“This report is part of a small but critical and growing body of evidence showing that food companies should improve the healthiness of their portfolios and disclosures. By not doing so, they increase their own risk and miss the opportunity to improve societal outcomes.”
Peter Elwin, Head of the Food and Land Use programme at Planet Tracker,
“Unhealthy food products are costing society and employers, but the issue is being overlooked by financial institutions. Regulation presents an increasing threat to companies profiting from producing unhealthy foods, but poor disclosure is hiding the risks. Our analysis shows that there could be investment opportunities associated with producing healthy food so there’s an incentive for investors to ask for change.”
Read the report here.
About ATNI
ATNI is a global non-profit founded in 2013 that exists for the sole purpose of transforming markets for nutrition. ATNI believes the private sector has an important role to play in fighting malnutrition. ATNI’s mission is to improve (financial) market performance by challenging key actors in the food system – notably industry and investors – to accelerate access to affordable, sustainable, and nutritious food for all, especially for society’s most vulnerable. ATNI does this through the development and publication of accountability tools and strategies in close collaboration with industry, investors, policymakers, consumers organizations and other nutrition stakeholders.
About Planet Tracker
Planet Tracker is an award-winning non-profit financial think tank aligning capital markets with planetary boundaries. Created with the vision of a financial system that is fully aligned with a net-zero, resilient, nature positive and just economy well before 2050, Planet Tracker generates break-through analytics that reveal both the role of capital markets in the degradation of our ecosystem and show the opportunities of transitioning to a zero-carbon, nature positive economy.
About GAIN
The Global Alliance for Improved Nutrition (GAIN) is a Swiss-based foundation launched at the United Nations in 2002 to tackle the human suffering caused by malnutrition. Working with governments, businesses and civil society, GAIN aims to transform food systems so that they deliver more nutritious foods for all people, especially the most vulnerable.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626413872/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press release
Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-endOmlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentationsMultiple dose strengths and device options broaden treatment flexibility for healthcare professionals Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release
QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
